Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTVNASDAQ:ERNANASDAQ:OTLKNASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$1.81-11.7%$3.01$1.78▼$17.31$44.10MN/A174,105 shs165,594 shsERNAEterna Therapeutics$0.25+13.1%$0.21$0.15▼$2.63$15.45M5.612.79 million shs685,160 shsOTLKOutlook Therapeutics$1.75-13.8%$1.43$0.87▼$9.25$56.03M0.39745,837 shs932,439 shsRENBRenovaro$0.33-1.6%$0.49$0.29▼$2.34$52.38M0.62965,733 shs1.75 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-11.71%-12.77%-7.65%-54.86%+180,999,900.00%ERNAEterna Therapeutics+13.11%+19.66%+18.74%-13.93%-89.46%OTLKOutlook Therapeutics-13.79%+24.11%+25.90%-4.89%-76.35%RENBRenovaro-1.55%+5.36%-7.95%-55.53%-68.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics1.9584 of 5 stars3.50.00.00.01.81.70.6ERNAEterna Therapeutics1.2748 of 5 stars0.05.00.00.02.01.70.6OTLKOutlook Therapeutics1.7937 of 5 stars3.43.00.00.01.90.00.6RENBRenovaro0.8664 of 5 stars0.02.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$20.401,027.07% UpsideERNAEterna Therapeutics 0.00N/AN/AN/AOTLKOutlook Therapeutics 2.80Moderate Buy$10.20482.86% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ERNA, RENB, ARTV, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/26/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.003/25/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.002/24/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $24.002/18/2025OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.002/18/2025OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $3.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$251K175.69N/AN/AN/A∞ERNAEterna Therapeutics$582K26.54N/AN/A$0.41 per share0.60OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ARENBRenovaroN/AN/AN/AN/A$0.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva BiotherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/23/2025 (Estimated)ERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%N/AOTLKOutlook Therapeutics-$75.37M-$7.42N/AN/AN/AN/AN/A-225.12%5/21/2025 (Estimated)RENBRenovaro-$80.65M-$0.93N/A∞N/AN/A-61.84%-48.07%N/ALatest ERNA, RENB, ARTV, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q2 2025OTLKOutlook Therapeutics-$0.55N/AN/AN/A$0.70 millionN/A5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/A2/19/2025Q2 2025RENBRenovaroN/A-$0.02N/A-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A11.3311.33ERNAEterna TherapeuticsN/A0.480.48OTLKOutlook TherapeuticsN/A0.320.64RENBRenovaroN/A0.060.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AERNAEterna Therapeutics70.55%OTLKOutlook Therapeutics11.20%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%ERNAEterna Therapeutics1.50%OTLKOutlook Therapeutics4.80%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 millionN/AN/AERNAEterna Therapeutics1062.36 million5.17 millionNo DataOTLKOutlook Therapeutics2032.02 million30.48 millionOptionableRENBRenovaro20158.72 million124.24 millionOptionableERNA, RENB, ARTV, and OTLK HeadlinesRecent News About These CompaniesRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformMay 14 at 9:15 AM | globenewswire.comRenovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiekMay 13 at 7:33 PM | nl.investing.comRenovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA DiagnosticsMay 13 at 9:15 AM | globenewswire.comRenovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLCMay 2, 2025 | marketbeat.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingenMay 1, 2025 | nl.investing.comRenovaro BioSciences expands collaboration with NebulApril 23, 2025 | markets.businessinsider.comRenovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI TechnologyApril 22, 2025 | quiverquant.comRenovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic ProgramsApril 22, 2025 | globenewswire.comRenovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoersApril 18, 2025 | nl.investing.comRenovaro BioSciences, BioSymetrics close merger transactionApril 9, 2025 | markets.businessinsider.comRenovaro Inc: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | finanznachrichten.deRenovaro fuseert met BioSymetrics voor AI-gedreven medicijnontwikkelingApril 9, 2025 | nl.investing.comRenovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | globenewswire.comPredictive Oncology Ends Merger Talks with RenovaroApril 7, 2025 | tipranks.comRenovaro Biosciences stuit op tegenslag bij fusie met Predictive OncologyApril 6, 2025 | nl.investing.comRenovaro Inc: Renovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | finanznachrichten.deRenovaro BioSciences provides update to agreement with Predictive OncologyApril 4, 2025 | markets.businessinsider.comRenovaro Shares Fall After Merger SetbackApril 4, 2025 | marketwatch.comRenovaro says Predictive Oncology terminates merger transactionApril 4, 2025 | markets.businessinsider.comRenovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | globenewswire.comRenovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive OncologyMarch 5, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2 Penny Stocks With $10 Potential By Thomas Hughes | April 16, 2025View 2 Penny Stocks With $10 Potential 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Is It Time to Load Up on Bond ETFs?By Nathan Reiff | May 2, 2025View Is It Time to Load Up on Bond ETFs?3 Stocks Lifting 2025 Guidance Despite Market JittersBy Leo Miller | April 29, 2025View 3 Stocks Lifting 2025 Guidance Despite Market Jitters2 Strong Utilities Plays With Booming Earnings and Room to GrowBy Nathan Reiff | April 24, 2025View 2 Strong Utilities Plays With Booming Earnings and Room to GrowERNA, RENB, ARTV, and OTLK Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$1.81 -0.24 (-11.71%) As of 05/14/2025 04:00 PM EasternArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Eterna Therapeutics NASDAQ:ERNA$0.25 +0.03 (+13.11%) As of 05/14/2025 04:00 PM EasternEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Outlook Therapeutics NASDAQ:OTLK$1.75 -0.28 (-13.79%) As of 05/14/2025 04:00 PM EasternOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Renovaro NASDAQ:RENB$0.33 -0.01 (-1.55%) As of 05/14/2025 04:00 PM EasternRenovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
